Pregnancy or breast feeding participant

Participant who had a current dental problem, particularly tooth or jaw infection, trauma or surgery on tooth or jaw in the previous six weeks, medical history of jaw osteonecrosis or delayed healing after dental surgery

Participant who was participating or had participated in the last 30 days to a clinical trial investigating treatments

Uncontrolled brain metastasis

Severe or concomitant infection

Known medical history of systemic disease with renal lesion

Rapidly progressing renal failure at inclusion

Uncontrolled cardiac disorder

Hypercalcaemia (\> 2.7 millimoles per liter \[mmol/L\]), hypocalcaemia (\< 2 mmol/L)

Participant receiving nephrotoxic chemotherapy

Participant eligible for haematopoietic stem cell transplantation at inclusion time

Bisphosphonate therapy in the 3 weeks before randomization

Known hypersensitivity to ibandronate or other bisphosphonates

A Study to Evaluate Renal Safety of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Due to Breast Cancer

What this study is about